Subscribe
bee32
bee32 / iStockphoto.com
31 October 2017Americas

PTAB grants rehearing of Genentech patent IPR

The Patent Trial and Appeal Board (PTAB) has agreed to rehear an inter partes review (IPR) filed by Hospira, a company now owned by Pfizer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB denies Celltrion’s patent challenge against Genentech
7 March 2017   The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
PTAB denies Celltrion’s patent challenge against Genentech
7 March 2017   The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.

More on this story

Americas
PTAB denies Celltrion’s patent challenge against Genentech
7 March 2017   The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers